ArticleThe New phytologist2025
Stereochemical insights into sarpagan and akuammiline alkaloid biosynthesis.
Article in The New phytologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ancient gene clusters govern the initiation of monoterpenoid indole alkaloid biosynthesis and C3 stereochemistry inversion.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sarpagan and akuammiline monoterpenoid indole alkaloids (MIAs) are a class of bioactive plant-derived compounds with significant pharmaceutical potential. These alkaloids are formed through oxidative cyclization of geissoschizine, catalyzed by homologous cytochrome P450 monooxygenases (CYP) known as sarpagan bridge enzymes (SBEs) and rhazimal synthases (RHSs). However, a long-standing discrepancy exists between the expected C16 stereochemistry of enzymatic products and the stereochemistry of naturally occurring derivatives. This study investigates C16 stereochemistry outcomes after geissoschizine cyclization and subsequent enzymatic transformations in six MIA-producing species. We combine comparative gene discovery, in planta gene silencing of Catharanthus roseus SBE, in vitro enzyme characterization, and intermediate nuclear magnetic resonance analysis. We identify and characterize five new CYPs and a new akuammidine aldehyde reductase alongside two known enzymes from Alstonia scholaris, Amsonia tabernaemontana, Catharanthus roseus, Rauvolfia serpentina, Tabernaemontana elegans, and Vinca minor. RHS enzymes consistently produce the 16R rhazimal stereoisomer. SBEs likely yield 16R polyneuridine aldehyde and, to a lesser extent, its 16S epimer akuammidine aldehyde. Downstream aldehyde reductases, deformylases, and decarbomethoxylases further epimerize C16, generating species-specific stereochemical diversity. This work demonstrates the enzymatic tailoring steps that govern C16 stereochemistry in sarpagan MIA biosynthesis, offering new insight into stereochemical diversification and pathway evolution in plant specialized metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.